Skip to content

Study on Radiological and functional Outcomes of total hip Arthroplasty in Patients with spinal and pelvic Imbalance Based on Artificial Intelligence mako 4.0

Study on Radiological and functional Outcomes of total hip Arthroplasty in Patients with spinal and pelvic Imbalance Based on Artificial Intelligence mako 4.0

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121654
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage hip joint disease who have spinal and pelvic imbalance

Interventions

Mako 4.0 assisted THA group:Mako 4.0 assisted surgery or not
cTHA group:Conventional surgical plan

Sponsors

Taizhou Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with end-stage hip disease; 2. Patients with spinal-pelvic misalignment; 3. Patients and their guardians are willing and able to sign an informed consent form prior to surgery and to undergo standard postoperative follow-up examinations.

Exclusion criteria

Exclusion criteria: 1. Neuromuscular disorders (e.g., paralysis, myasthenia gravis) affecting lower limb function; 2. Bone tumors, infectious arthritis; 3. Severe cardiopulmonary, hepatic, or renal dysfunction; or psychiatric disorders that prevent the patient from complying with or understanding the study requirements; 4. Patients expected to have poor compliance.

Design outcomes

Primary

MeasureTime frame
Functional outcome data;Radiological data: Anatomical parameters of the hip joint and spinal pelvis parameters of the patients were collected during preoperative and postoperative follow-ups respectively;

Countries

China

Contacts

Public ContactChenglong Wang

Taizhou Hospital of Zhejiang Province

wangcl4779@enzemed.com+86 198 8365 2936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026